Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 1-Year Low – Here’s Why

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $665.04 and last traded at $666.41, with a volume of 31218 shares changing hands. The stock had previously closed at $672.98.

Analysts Set New Price Targets

Several equities research analysts have commented on REGN shares. Oppenheimer lowered their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

The stock’s fifty day moving average price is $720.81 and its two-hundred day moving average price is $921.72. The firm has a market capitalization of $73.34 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $37,000. Private Wealth Management Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.